IMMUNOSERV_LTD - Accounts


Company registration number 12962520 (England and Wales)
IMMUNOSERV LTD
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2022
PAGES FOR FILING WITH REGISTRAR
IMMUNOSERV LTD
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 7
IMMUNOSERV LTD
BALANCE SHEET
AS AT 31 OCTOBER 2022
31 October 2022
- 1 -
2022
2021
Notes
£
£
£
£
Fixed assets
Intangible assets
3
2,000
2,500
Tangible assets
4
46,387
14,272
48,387
16,772
Current assets
Stocks
33,455
5,002
Debtors
5
25,753
16,019
Cash at bank and in hand
85,038
47,154
144,246
68,175
Creditors: amounts falling due within one year
6
(110,813)
(67,127)
Net current assets
33,433
1,048
Total assets less current liabilities
81,820
17,820
Provisions for liabilities
(8,343)
(778)
Net assets
73,477
17,042
Capital and reserves
Called up share capital
7
100
100
Profit and loss reserves
73,377
16,942
Total equity
73,477
17,042

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 October 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 28 February 2023 and are signed on its behalf by:
Mr M J Scurr
Director
Company Registration No. 12962520
IMMUNOSERV LTD
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 OCTOBER 2022
- 2 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 20 October 2020
-
0
-
0
-
Period ended 31 October 2021:
Profit and total comprehensive income for the period
-
16,942
16,942
Issue of share capital
7
100
-
100
Balance at 31 October 2021
100
16,942
17,042
Year ended 31 October 2022:
Profit and total comprehensive income for the year
-
56,435
56,435
Balance at 31 October 2022
100
73,377
73,477
IMMUNOSERV LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2022
- 3 -
1
Accounting policies
Company information

Immunoserv Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Unit 8 Cae Gwyrdd, Tongwynlais, Cardiff, CF15 7AB.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

1.3
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Software
20% on cost
1.4
Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
20% on cost
Computers
20% on cost
1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

IMMUNOSERV LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2022
1
Accounting policies
(Continued)
- 4 -

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.6
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

 

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.8
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

1.9
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.10
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease.

IMMUNOSERV LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2022
- 5 -
2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2022
2021
Number
Number
Total
7
2
3
Intangible fixed assets
Software
£
Cost
At 1 November 2021 and 31 October 2022
2,500
Amortisation and impairment
At 1 November 2021
-
0
Amortisation charged for the year
500
At 31 October 2022
500
Carrying amount
At 31 October 2022
2,000
At 31 October 2021
2,500
4
Tangible fixed assets
Plant and equipment
Computers
Total
£
£
£
Cost
At 1 November 2021
16,605
-
0
16,605
Additions
34,091
5,737
39,828
At 31 October 2022
50,696
5,737
56,433
Depreciation and impairment
At 1 November 2021
2,333
-
0
2,333
Depreciation charged in the year
6,982
731
7,713
At 31 October 2022
9,315
731
10,046
Carrying amount
At 31 October 2022
41,381
5,006
46,387
At 31 October 2021
14,272
-
0
14,272
IMMUNOSERV LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2022
- 6 -
5
Debtors
2022
2021
Amounts falling due within one year:
£
£
Trade debtors
6,215
5,059
Corporation tax recoverable
16,752
9,592
Other debtors
2,786
1,368
25,753
16,019
6
Creditors: amounts falling due within one year
2022
2021
£
£
Trade creditors
40,630
9,623
Taxation and social security
15,916
5,388
Other creditors
54,267
52,116
110,813
67,127
7
Called up share capital
2022
2021
2022
2021
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
100
100
100
100
8
Operating lease commitments
Lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2022
2021
£
£
5,072
19,019
IMMUNOSERV LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2022
- 7 -
9
Directors' transactions

Advances or credits have been granted by the company to its directors as follows:

Description
% Rate
Opening balance
Amounts repaid
Closing balance
£
£
£
Directors
-
100
(39,160)
(39,060)
100
(39,160)
(39,060)
2022-10-312021-11-01false28 February 2023CCH SoftwareCCH Accounts Production 2022.300No description of principal activityMiss Lara JacobsMr M J ScurrMr A J GodkinMr J P Hindley129625202021-11-012022-10-31129625202022-10-31129625202021-10-3112962520core:ComputerSoftware2022-10-3112962520core:ComputerSoftware2021-10-3112962520core:PlantMachinery2022-10-3112962520core:ComputerEquipment2022-10-3112962520core:PlantMachinery2021-10-3112962520core:ComputerEquipment2021-10-3112962520core:CurrentFinancialInstrumentscore:WithinOneYear2022-10-3112962520core:CurrentFinancialInstrumentscore:WithinOneYear2021-10-3112962520core:CurrentFinancialInstruments2022-10-3112962520core:CurrentFinancialInstruments2021-10-3112962520core:ShareCapital2022-10-3112962520core:ShareCapital2021-10-3112962520core:RetainedEarningsAccumulatedLosses2022-10-3112962520core:RetainedEarningsAccumulatedLosses2021-10-3112962520core:ShareCapital2020-10-1912962520core:RetainedEarningsAccumulatedLosses2020-10-1912962520bus:Director22021-11-012022-10-3112962520core:RetainedEarningsAccumulatedLosses2020-10-202021-10-31129625202020-10-202021-10-3112962520core:RetainedEarningsAccumulatedLosses2021-11-012022-10-3112962520core:ShareCapital2020-10-202021-10-3112962520core:IntangibleAssetsOtherThanGoodwill2021-11-012022-10-3112962520core:ComputerSoftware2021-11-012022-10-3112962520core:PlantMachinery2021-11-012022-10-3112962520core:ComputerEquipment2021-11-012022-10-3112962520core:ComputerSoftware2021-10-3112962520core:PlantMachinery2021-10-3112962520core:ComputerEquipment2021-10-31129625202021-10-3112962520core:WithinOneYear2022-10-3112962520core:WithinOneYear2021-10-3112962520bus:PrivateLimitedCompanyLtd2021-11-012022-10-3112962520bus:SmallCompaniesRegimeForAccounts2021-11-012022-10-3112962520bus:FRS1022021-11-012022-10-3112962520bus:AuditExemptWithAccountantsReport2021-11-012022-10-3112962520bus:Director12021-11-012022-10-3112962520bus:Director32021-11-012022-10-3112962520bus:Director42021-11-012022-10-3112962520bus:FullAccounts2021-11-012022-10-31xbrli:purexbrli:sharesiso4217:GBP